Evidence map›Paper›PMID 35159318›Full record

Trial reportCells2022

Decreased Concentration of Fibroblast Growth Factor 23 (FGF-23) as a Result of Supplementation with Selenium and Coenzyme Q

Urban Alehagen, Jan Aaseth, Anders Larsson, Jan Alexander

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05942027 (Clinical Study Evaluating the Role of Coenzyme Q10 as Adjuvant Therapy to Angiotensin Converting Enzyme Inhibitor on Blood Pressure, Proteinuria and Bone Metabolism in Patients With Chronic Kidney Disease), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05942027 phase4recruitingnot on this mapstarted 2023, after this paper: background citation

Clinical Study Evaluating the Role of Coenzyme Q10 as Adjuvant Therapy to Angiotensin Converting Enzyme Inhibitor on Blood Pressure, Proteinuria and Bone Metabolism in Patients With Chronic Kidney Disease

TypeinterventionalSponsorTanta UniversityRan2023 to 2026Enrolled44ConditionsChronic Kidney DiseasesArmsPlacebo, Co-Enzyme Q10
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Urban AlehagenDivision of Cardiovascular Medicine, Department of Health, Medicine and Caring Sciences, Linköping University, 81 85 Linköping, Sweden.
Jan AasethResearch Department, Innlandet Hospital Trust, 2381 Brumunddal, Norway.ORCID 0000-0002-7518-5703
Anders LarssonDepartment of Medical Sciences, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0003-3161-0402
Jan AlexanderNorwegian Institute of Public Health, 0403 Oslo, Norway.ORCID 0000-0002-6381-5720
Innlandet Hospital Trust · NOLinköping University · SENorwegian Institute of Public Health · NOUppsala University · SE

Funding

County Council of Östergötland, Linköping, SwedenPharmaNord, Vejle, Denmark
6 · The paper itself

Abstract

There is a reduced intake of selenium in many countries due to low levels of selenium in the soil. This results in an increased cardiovascular risk. Fibroblast growth factor 23 (FGF-23) is active mainly in the metabolism of vitamin D and phosphorus. However, there are indications that FGF-23 may also provide information both on cardiovascular function and prognosis. The aim of the study was to evaluate the effect of supplementation with selenium and coenzyme Q

Indexed as

Cardiovascular DiseasesSeleniumAgedDietary SupplementsFibroblast Growth Factor-23Fibroblast Growth FactorsHumansProspective StudiesSwedenUbiquinoneFibroblast Growth Factor-23Fibroblast Growth FactorsSeleniumUbiquinonecoenzyme Q10elderlyFGF-23interventionselenium

Identifiers

PMID35159318
PMCPMC8834214
OpenAlexW4210629743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.